Cargando…
Measuring Nasal Patency and the Sense of Smell in CRSwNP Patients Treated with Dupilumab
Chronic rhinosinusitis with nasal polyps (CRSwNP) in the most severe forms is associated with a poor quality of life. Dupilumab has been suggested as an add-on treatment option for severe CRSwNP. Severe CRSwNP patients treated with dupilumab in different rhinological units were followed up at 1, 3,...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962970/ https://www.ncbi.nlm.nih.gov/pubmed/36836468 http://dx.doi.org/10.3390/jpm13020234 |
_version_ | 1784896134602293248 |
---|---|
author | Ottaviano, Giancarlo De Corso, Eugenio Cantone, Elena Ciofalo, Andrea Saccardo, Tommaso Bernardi, Riccardo Mairani, Edoardo Montuori, Claudio Roccuzzo, Giuseppe Soldati, Livia Randon, Benedetto Zampollo, Sonny Chicco, Alessandra Di Visconti, Francesca Scarpa, Bruno Nicolai, Piero |
author_facet | Ottaviano, Giancarlo De Corso, Eugenio Cantone, Elena Ciofalo, Andrea Saccardo, Tommaso Bernardi, Riccardo Mairani, Edoardo Montuori, Claudio Roccuzzo, Giuseppe Soldati, Livia Randon, Benedetto Zampollo, Sonny Chicco, Alessandra Di Visconti, Francesca Scarpa, Bruno Nicolai, Piero |
author_sort | Ottaviano, Giancarlo |
collection | PubMed |
description | Chronic rhinosinusitis with nasal polyps (CRSwNP) in the most severe forms is associated with a poor quality of life. Dupilumab has been suggested as an add-on treatment option for severe CRSwNP. Severe CRSwNP patients treated with dupilumab in different rhinological units were followed up at 1, 3, 6 and 12 months from the first administration and were considered for this study. At baseline (T0) and at each follow-up, patients underwent nasal endoscopy and completed the sinonasal outcome test (SNOT)-22, a visual analogue scale (VAS) for smell/nasal obstruction, peak nasal inspiratory flow (PNIF) and the Sniffin’ Sticks identification test (SSIT). The aim of the present study was to evaluate the effects of dupilumab in patients with severe uncontrolled CRSwNP on recovering nasal obstruction and smell impairment. Moreover, the method between PNIF and SSIT with the highest correlation with patients’ response to dupilumab was evaluated. One hundred forty-seven patients were included. All parameters improved during treatment (p < 0.001). At T0, no correlations were found between PNIF and nasal symptoms. Nevertheless, during the following evaluations significant correlations between PNIF changes and both nasal symptoms and NPS were observed (p < 0.05). At T0, SSIT did not correlate with SNOT-22. Similarly to PNIF, during the follow-up SSIT changes significantly correlated with nasal symptom and NPS (p < 0.05). Comparing PNIF and SSIT correlations with SNOT-22 and NPS, PNIF showed a higher correlation with both. Dupilumab improves nasal obstruction and the sense of smell. PNIF and SSIT are effective tools in monitoring patients’ response to dupilumab. |
format | Online Article Text |
id | pubmed-9962970 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99629702023-02-26 Measuring Nasal Patency and the Sense of Smell in CRSwNP Patients Treated with Dupilumab Ottaviano, Giancarlo De Corso, Eugenio Cantone, Elena Ciofalo, Andrea Saccardo, Tommaso Bernardi, Riccardo Mairani, Edoardo Montuori, Claudio Roccuzzo, Giuseppe Soldati, Livia Randon, Benedetto Zampollo, Sonny Chicco, Alessandra Di Visconti, Francesca Scarpa, Bruno Nicolai, Piero J Pers Med Communication Chronic rhinosinusitis with nasal polyps (CRSwNP) in the most severe forms is associated with a poor quality of life. Dupilumab has been suggested as an add-on treatment option for severe CRSwNP. Severe CRSwNP patients treated with dupilumab in different rhinological units were followed up at 1, 3, 6 and 12 months from the first administration and were considered for this study. At baseline (T0) and at each follow-up, patients underwent nasal endoscopy and completed the sinonasal outcome test (SNOT)-22, a visual analogue scale (VAS) for smell/nasal obstruction, peak nasal inspiratory flow (PNIF) and the Sniffin’ Sticks identification test (SSIT). The aim of the present study was to evaluate the effects of dupilumab in patients with severe uncontrolled CRSwNP on recovering nasal obstruction and smell impairment. Moreover, the method between PNIF and SSIT with the highest correlation with patients’ response to dupilumab was evaluated. One hundred forty-seven patients were included. All parameters improved during treatment (p < 0.001). At T0, no correlations were found between PNIF and nasal symptoms. Nevertheless, during the following evaluations significant correlations between PNIF changes and both nasal symptoms and NPS were observed (p < 0.05). At T0, SSIT did not correlate with SNOT-22. Similarly to PNIF, during the follow-up SSIT changes significantly correlated with nasal symptom and NPS (p < 0.05). Comparing PNIF and SSIT correlations with SNOT-22 and NPS, PNIF showed a higher correlation with both. Dupilumab improves nasal obstruction and the sense of smell. PNIF and SSIT are effective tools in monitoring patients’ response to dupilumab. MDPI 2023-01-28 /pmc/articles/PMC9962970/ /pubmed/36836468 http://dx.doi.org/10.3390/jpm13020234 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Ottaviano, Giancarlo De Corso, Eugenio Cantone, Elena Ciofalo, Andrea Saccardo, Tommaso Bernardi, Riccardo Mairani, Edoardo Montuori, Claudio Roccuzzo, Giuseppe Soldati, Livia Randon, Benedetto Zampollo, Sonny Chicco, Alessandra Di Visconti, Francesca Scarpa, Bruno Nicolai, Piero Measuring Nasal Patency and the Sense of Smell in CRSwNP Patients Treated with Dupilumab |
title | Measuring Nasal Patency and the Sense of Smell in CRSwNP Patients Treated with Dupilumab |
title_full | Measuring Nasal Patency and the Sense of Smell in CRSwNP Patients Treated with Dupilumab |
title_fullStr | Measuring Nasal Patency and the Sense of Smell in CRSwNP Patients Treated with Dupilumab |
title_full_unstemmed | Measuring Nasal Patency and the Sense of Smell in CRSwNP Patients Treated with Dupilumab |
title_short | Measuring Nasal Patency and the Sense of Smell in CRSwNP Patients Treated with Dupilumab |
title_sort | measuring nasal patency and the sense of smell in crswnp patients treated with dupilumab |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962970/ https://www.ncbi.nlm.nih.gov/pubmed/36836468 http://dx.doi.org/10.3390/jpm13020234 |
work_keys_str_mv | AT ottavianogiancarlo measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab AT decorsoeugenio measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab AT cantoneelena measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab AT ciofaloandrea measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab AT saccardotommaso measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab AT bernardiriccardo measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab AT mairaniedoardo measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab AT montuoriclaudio measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab AT roccuzzogiuseppe measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab AT soldatilivia measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab AT randonbenedetto measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab AT zampollosonny measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab AT chiccoalessandradi measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab AT viscontifrancesca measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab AT scarpabruno measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab AT nicolaipiero measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab |